byAmerican Society for Radiation OncologyMammograms showing a normal breast (left) and a breast with cancer (right). Credit: Public DomainA three-week course of radiation therapy is as safe and
byAmerican Society for Radiation OncologyMammograms showing a normal breast (left) and a breast with cancer (right). Credit: Public DomainA three-week course of radiation therapy is as safe and
byCancer Research UK| News15 May 2019Less chemotherapy is as effective at controlling disease for elderly or frail patients with advanced cancer of the stomach or oesophagus (food pipe), a
byCancer Research UK| News15 May 2019Less chemotherapy is as effective at controlling disease for elderly or frail patients with advanced cancer of the stomach or oesophagus (food pipe), a
by Cancer CouncilCredit: Pixabay/CC0 Public DomainA new study by the Daffodil Center, published in theBritish Journal of Cancer, has strengthened the economic case for a targeted lung cancer scr
by Cancer CouncilCredit: Pixabay/CC0 Public DomainA new study by the Daffodil Center, published in theBritish Journal of Cancer, has strengthened the economic case for a targeted lung cancer scr
byEuropean Society for Medical OncologyCredit: European Society for Medical OncologyWomen with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower r
byEuropean Society for Medical OncologyCredit: European Society for Medical OncologyWomen with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower r
by Bob Yirka , Medical XpressTreatment with 3-IAA and FIRINOX results in reduced autophagic activity. a, Gnotobiotic mice were colonized with R microbiota and KPC cells were orthotopically injected. M
by Bob Yirka , Medical XpressTreatment with 3-IAA and FIRINOX results in reduced autophagic activity. a, Gnotobiotic mice were colonized with R microbiota and KPC cells were orthotopically injected. M
by Caroline Wallace,Medical University of South CarolinaCredit: Unsplash/CC0 Public DomainSouth Carolina is seeing one of the fastest rises in anal cancer incidence among women and anal cancer m
by Caroline Wallace,Medical University of South CarolinaCredit: Unsplash/CC0 Public DomainSouth Carolina is seeing one of the fastest rises in anal cancer incidence among women and anal cancer m
by Neil Schoenherr,Washington University in St. LouisChildhood and adolescent cancer survival in the United States does not vary by rural/urban residence at the time of diagnosis, finds a new st
by Neil Schoenherr,Washington University in St. LouisChildhood and adolescent cancer survival in the United States does not vary by rural/urban residence at the time of diagnosis, finds a new st
byVirginia Commonwealth UniversityCredit: Unsplash/CC0 Public DomainResearchers at VCU Massey Cancer Center discovered a cellular partnership that drives the growth of deadly brain tumors and co
byVirginia Commonwealth UniversityCredit: Unsplash/CC0 Public DomainResearchers at VCU Massey Cancer Center discovered a cellular partnership that drives the growth of deadly brain tumors and co
byUNC Lineberger Comprehensive Cancer CenterA new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked he
byUNC Lineberger Comprehensive Cancer CenterA new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked he
byInstitute of Cancer ResearchMicrograph of seminoma testes showing lobules of uniform cells separated by delicate septae of fibrous tissue. Credit: Calicut Medical College via Wikimedia. Licens
byInstitute of Cancer ResearchMicrograph of seminoma testes showing lobules of uniform cells separated by delicate septae of fibrous tissue. Credit: Calicut Medical College via Wikimedia. Licens
The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.